GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced that its Board of Directors has approved a 1-for-24 reverse stock split of its common stock. The split, approved by stockholders on October 27, 2026, is intended to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The split becomes effective at 12:01 a.m. ET on November 11, 2026, and shares are expected to begin trading on a split-adjusted basis at the market open, according to a press release distributed via NEWMEDIAWIRE.
Under the split, every 24 issued and outstanding shares will automatically convert into one share, reducing the total share count from 12,209,871 to approximately 508,745. The common stock will continue to trade under the symbol “GOVX” with a new CUSIP number, 373678 804. The par value per share remains unchanged at $0.001. Each stockholder’s percentage ownership interest and proportional voting power will remain unchanged, except for minor adjustments from rounding fractional shares to the nearest whole number. The rights and privileges of common stockholders will be substantially unaffected.
This reverse split is important because it directly addresses the company’s listing status. Falling below Nasdaq’s minimum bid price can lead to delisting, which would reduce liquidity, limit access to capital and potentially undermine investor confidence. By regaining compliance, GeoVax aims to maintain its presence on a major exchange, preserving visibility and trading access for shareholders. For a clinical-stage biotech with no marketed products, maintaining a Nasdaq listing is often critical for raising the capital needed to fund costly research and development.
GeoVax is advancing GEO-MVA, a Modified Vaccinia Ankara–based vaccine targeting mpox and smallpox, under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 trial in late 2026. In oncology, it is developing Gedeptin®, a gene-directed enzyme prodrug therapy that has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies. The company maintains a global intellectual property portfolio and continues to evaluate strategic partnerships and funding opportunities. More information is available at www.geovax.com.
While the split does not change the economic value of stockholders’ proportional stakes in theory, it often serves as a signal that a company’s share price has declined significantly. Investors and industry observers will watch whether the move achieves its immediate goal of compliance and whether GeoVax can execute on its clinical milestones to support its longer-term valuation.
